6 results on '"S Metallidis"'
Search Results
2. MARKERS OF ARTERIAL STIFFNESS AND ATHEROSCLEROSIS IN HIV-INFECTED INDIVIDUALS
- Author
-
C. Gogou, A. Gogou, Pantelis Zebekakis, Lemonia Skoura, Marianthi Papagianni, Maria P. Yavropoulou, D. Chatzidimitriou, P. Collaras, Maria Pikilidou, T. Chrysanthidis, S. Nanoudis, G. Loli, O. Tsachouridou, and S. Metallidis
- Subjects
Physiology ,business.industry ,Hiv infected ,Immunology ,Internal Medicine ,Arterial stiffness ,medicine ,Cardiology and Cardiovascular Medicine ,medicine.disease ,business - Published
- 2018
- Full Text
- View/download PDF
3. FACTORS AFFECTING CAROTID-FEMORAL PULSE WAVE VELOCITY IN HIV-INFECTED INDIVIDUALS
- Author
-
T. Chrisanthidis, C. Gogou, Lemonia Skoura, Marianthi Papagianni, Maria Pikilidou, O. Tsachouridou, S. Metallidis, D. Chatzidimitriou, A. Georgiou, P. Collaras, Pantelis Zebekakis, S. Nanoudis, Maria P. Yavropoulou, and G. Loli
- Subjects
medicine.medical_specialty ,Physiology ,business.industry ,Internal medicine ,Hiv infected ,Internal Medicine ,medicine ,Cardiology ,Cardiology and Cardiovascular Medicine ,business ,Pulse wave velocity - Published
- 2018
- Full Text
- View/download PDF
4. In-VitroActivity of Clinafloxacin Compared to Ciprofloxacin AgainstAcinetobacter baumanniiStrains Isolated from Intensive Care Unit Patients
- Author
-
P, Nikolaidis, S, Metallidis, P, Kollaras, A, Tsona, E, Koumedaki, D, Tsaousoglu, and E, Loumedaki
- Subjects
Acinetobacter baumannii ,Critical Care ,Microbial Sensitivity Tests ,Microbiology ,law.invention ,chemistry.chemical_compound ,Anti-Infective Agents ,Ciprofloxacin ,law ,Intensive care ,Drug Resistance, Bacterial ,polycyclic compounds ,Humans ,Medicine ,Pharmacology (medical) ,Etest ,Antibacterial agent ,Pharmacology ,biology ,business.industry ,biochemical phenomena, metabolism, and nutrition ,bacterial infections and mycoses ,biology.organism_classification ,Intensive care unit ,Infectious Diseases ,Oncology ,chemistry ,bacteria ,Neisseriaceae ,business ,Clinafloxacin ,Acinetobacter Infections ,Fluoroquinolones ,medicine.drug - Abstract
The activity of clinafloxacin was compared to that of ciprofloxacin against 154 Acinetobacter baumannii strains isolated from patients treated in Intensive Care Units. Minimum inhibitory concentrations (MICs) were determined by the Epsilometer test method. The majority (87.6%) of the A. baumannii strains tested were resistant to ciprofloxacin (MIC range 0.125->32, MIC50 =>32, MIC90 =>32). On the contrary, only 9.7% of the strains tested were resistant to clinafloxacin (MIC range 0.023->4, MIC50 =0.75, MIC90 =2). Due to its superior activity shown against A. baumannii strains, compared to ciprofloxacin, clinafloxacin may be added to the therapeutic armamentarium for hospital-acquired infections caused by A. baumannii in Intensive Care Units.
- Published
- 2002
- Full Text
- View/download PDF
5. P-208 Atypical feature of Sweet's syndrome in patient with myelodysplastic syndrome in transformation to acute myeloid leukemia
- Author
-
N. Kakaletsis, I. Poursanidis, A. Grekou, S. Metallidis, V. Tzalokostas, Vasilios Perifanis, Georgia Kaiafa, C. Savopoulos, A. Hatzitolios, and F. Iliadis
- Subjects
Sweet's syndrome ,Cancer Research ,Transformation (genetics) ,Oncology ,business.industry ,Feature (computer vision) ,Cancer research ,Medicine ,Myeloid leukemia ,In patient ,Hematology ,business ,medicine.disease - Published
- 2013
- Full Text
- View/download PDF
6. Fostemsavir in Adults with Multidrug-Resistant HIV-1 Infection
- Author
-
Michael, Kozal, Judith, Aberg, Gilles, Pialoux, Pedro, Cahn, Melanie, Thompson, Jean-Michel, Molina, Beatriz, Grinsztejn, Ricardo, Diaz, Antonella, Castagna, Princy, Kumar, Gulam, Latiff, Edwin, DeJesus, Mark, Gummel, Margaret, Gartland, Amy, Pierce, Peter, Ackerman, Cyril, Llamoso, Max, Lataillade, A, Wurcel, Yale School of Medicine [New Haven, Connecticut] (YSM), Icahn School of Medicine at Mount Sinai [New York] (MSSM), CHU Tenon [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Fundación Huésped [Buenos Aires], Université Paris Diderot, Sorbonne Paris Cité, Paris, France, Université Paris Diderot - Paris 7 (UPD7), Fundação Oswaldo Cruz (FIOCRUZ), Réseau International des Instituts Pasteur (RIIP), Federal University of Sao Paulo (Unifesp), IRCCS San Raffaele Scientific Institute [Milan, Italie], Georgetown University [Washington] (GU), Orlando Immunology Center, GlaxoSmithKline, Glaxo Smith Kline, GlaxoSmithKline [Research Triangle Park] (GSK ), ViiV Healthcare US, ViiV Healthcare [Brentford, UK], BRIGHTE Trial Team: P Cahn, L Cassetti, D O David, E Loiza, D Cecchini, S Lupo, M Martins, C Zala, A Carr, J McMahon, S De Wit, E Florence, C R Alves, J Andrade Neto, M Della Negra, R Diaz, B Grinsztejn, J Madruga, K Morejon, F Ribeiro, E Sprinz, M Murray, J Szabo, S Trottier, S Walmsley, J Ballesteros, F Zamora, C Beltran, C Chahin Anania, C Perez, M Wolff Reyes, J Velez, P M Girard, C Katlama, J-M Molina, D Neau, G Pialoux, I Poizot-Martin, F Raffi, D Salmon-Ceron, K Arastéh, A Baumgarten, J Bogner, M Hower, W Kern, D Schürmann, C Stephan, S Metallidis, V Paparizos, P Mallon, A Antinori, R Cauda, A Lazzarin, G Migliorino, C Mussini, G Orofino, G Rizzardini, P F Belaunzaran, R Cabello, J Duque Rodríguez, M Santoscoy-Gómez, S C Treviño, I Hoepelman, F Mendo, Y Pinedo Ramirez, M Parczewski, B Knysz, N Janeiro, F Maltez, L Preotescu, A Streinu-Cercel, G Latiff, I Mitha, J M Libre Codina, S Moreno Guillén, J Pineda, S M Hsieh, A Pozniak, J Aberg, J Bartczak, M Berhe, T Campbell, C Creticos, E DeJesus, V Drelichman, C Durand, J Eron, C Fichtenbaum, R Grossberg, S Gupta, F Haas, D Hagins, M Jain, M Kozal, P Kumar, J Lalezari, J Lennox, R Loftus, R Lubelchek, J McGowan, M McKellar, A Mills, J Morales-Ramirez, O Osiyemi, N Ramgopal, S Schrader, J Slim, P Tebas, M Thompson, W Towner, T Wilkin, A Wurcel, Malbec, Odile, Kozal, M., Aberg, J., Pialoux, G., Cahn, P., Thompson, M., Molina, J. -M., Grinsztejn, B., Diaz, R., Castagna, A., Kumar, P., Latiff, G., Dejesus, E., Gummel, M., Gartland, M., Pierce, A., Ackerman, P., Llamoso, C., Lataillade, M., Yale University School of Medicine, and Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)
- Subjects
Adult ,Male ,[SDV]Life Sciences [q-bio] ,Human immunodeficiency virus (HIV) ,HIV Infections ,Drug resistance ,030204 cardiovascular system & hematology ,medicine.disease_cause ,Piperazines ,law.invention ,03 medical and health sciences ,0302 clinical medicine ,Pharmacotherapy ,Drug Resistance, Multiple, Viral ,Randomized controlled trial ,law ,Humans ,Medicine ,Prodrugs ,030212 general & internal medicine ,Aged ,business.industry ,General Medicine ,Middle Aged ,Viral Load ,Virology ,Organophosphates ,CD4 Lymphocyte Count ,3. Good health ,[SDV] Life Sciences [q-bio] ,Clinical trial ,Multiple drug resistance ,Fostemsavir ,Anti-Retroviral Agents ,Multicenter study ,HIV-1 ,RNA, Viral ,Drug Therapy, Combination ,Female ,business - Abstract
International audience; Background: Among some patients with human immunodeficiency virus type 1 (HIV-1) infection who have undergone multiple antiretroviral therapies and have limited options for treatment, new classes of antiretroviral drugs with novel mechanisms of action are needed. Fostemsavir is the prodrug of temsavir, a first-in-class investigational HIV-1 attachment inhibitor.Methods: In this ongoing phase 3 trial in 23 countries, we enrolled patients with multidrug-resistant HIV-1 infection in two cohorts, according to their remaining treatment options. In the first cohort, we assigned (in a 3:1 ratio) patients who had the option of using at least one fully active, approved antiretroviral drug in at least one but no more than two antiretroviral classes to add either fostemsavir (at a dose of 600 mg twice daily) or placebo to their failing regimen for 8 days, followed by open-label fostemsavir plus optimized background therapy (randomized cohort). In the second cohort, patients who had no remaining antiretroviral options were started on open-label fostemsavir plus optimized background therapy on day 1 (nonrandomized cohort). The primary end point was the mean change in the HIV-1 RNA level from day 1 through day 8 in the randomized cohort.Results: A total of 371 patients were treated, including 272 in the randomized cohort and 99 in the nonrandomized cohort. At day 8, the mean decrease in the HIV-1 RNA level was 0.79 log10 copies per milliliter in the fostemsavir group and 0.17 log10 copies in the placebo group (P
- Published
- 2020
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.